Oxidative stress and microcirculatory flow abnormalities in the ventricles during atrial fibrillation

Frontiers in Physiology

Volumn 3 JUL, Issue , 2012, Pages

  Goette, Andreas ^a   Bukowska, Alicja ^b   Lillig, Christopher H ^c   Lendeckel, Uwe ^c  

^a St Vincenz Hospital   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Angiotensin; Atrial fibrillation; Microvascular flow; Oxidative stress

Indexed keywords

EID: 84866561577     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00236     Document Type: Review

References (101)

1. Abidov, A., Hachamovitch, R., Rozanski, A., Hayes, S. W., Santos, M. M., Sciammarella, M. G., Cohen, I., Ger-lach, J., Friedman, J. D., Germano, G., and Berman, D. S. (2004). Prognostic implications of atrial fibrillation in patients undergoing myocar-dial perfusion single-photon emission computed tomography. J. Am. Coll. Cardiol. 44, 1062-1070.
2. ACTIVE I Investigators, Yusuf, S., Healey, J. S., Pogue, J., Chrolavicius, S., Flather, M., Hart, R. G., Hohnloser, S. H., Joyner, C. D., Pfeffer, M. A., and Connolly, S. J. (2011). Irbe-sartan in patients with atrial fibrillation. N. Engl. J. Med. 364, 928-938.
3. Afanas'ev, I. (2011). ROS and RNS signaling in heart disorders: could antioxidant treatment be successful? Oxid. Med. Cell. Longev. 2011, 293769. doi: 10.1155/2011/293769
4. Ago, T., Kuroda, J., Pain, J., Fu, C., Li, H., and Sadoshima, J. (2010). Upregulation of NOX4 by hyper-trophic stimuli promotes apopto-sis and mitochondrial dysfunction in cardiac myocytes. Circ. Res. 106, 1253-1264.
5. Ago, T., Liu, T., Zhai, P., Chen, W., Li, H., Molkentin, J. D., Vatner, S. F., and Sadoshima, J. (2008). A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133, 978-993.
6. Ahmad, A., Ahmad, S., Schneider, B. K., Allen, C. B., Chang, L. Y., and White, C. W. (2002). Elevated expression of hexokinase II protects human lung epithelial-like A549 cells against oxidative injury. Am. J. Physiol. Lung Cell Mol. Physiol. 283, L573-L584.
7. Amiri, F., Virdis, A., Neves, M. F., Iglarz, M., Seidah, N. G., Touyz, R. M., Reudelhuber, T. L., and Schiffrin,E. L.(2004). Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110, 2233-2240.
8. Antoniades, C., Demosthenous, M., Reilly, S., Margaritis, M., Zhang, M. H., Antonopoulos, A., Marinou, K., Nahar, K., Jayaram, R., Tousoulis, D., Bakogiannis, C., Sayeed, R., Triantafyllou, C., Koumallos, N., Psar-ros, C., Miliou, A., Stefanadis, C., Channon, K. M., and Casadei, B. (2012). Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J. Am. Coll. Cardiol. 59, 60-70.
9. Arany, Z., Foo, S. Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M., Laznik, D., Chinsom-boon, J., Rangwala, S. M., Baek, K. H., Rosenzweig, A., and Spiegelman, B. M. (2008). HIF-independent regulation of VEGF and angiogen-esis by the transcriptional coac-tivator PGC-1alpha. Nature 451, 1008-1012.
10. Babior, B. M., Lambeth, J. D., and Nauseef, W. (2002). The neutrophil NADPH oxidase. Arch. Biochem. Biophys. 397, 342-324.
11. Bayraktutan, U., Blayney, L., and Shah, A. M. (2000). Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20, 1903-1911.
12. Bendall, J. K., Cave, A. C., Heymes, C., Gall, N., and Shah,A. M. (2002). Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105, 293-296.
13. Berndt, C., Lillig, C. H., and Holmgren, A. (2007). Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 292, H1227-H1236.
14. Besse, S., Tanguy, S., Riou, B., Boucher, F., Bulteau, A. L., Le Page, C., Swynghedauw, B., and de Leiris, J. (2001). Coronary and aortic vasoreactivity protection with endothelin receptor antagonist, bosentan, after ischemia and hypoxia in aged rats. Eur. J. Pharmacol. 432, 167-175.
15. Bloom, D. A., and Jaiswal, A. K. (2003). Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H: quinone oxidoreductase-1 gene expression. J. Biol. Chem. 278, 44675-44682.
16. Bolukoglu, H., Goodwin, G. W., Guthrie, P. H., Carmical, S. G., Chen, T. M., and Taegtmeyer, H. (1996). Metabolic fate of glucose in reversible low-flow ischemia of the isolated working rat heart. Am. J. Physiol. 270(Pt 2), H817-H826.
17. Bonello, S., Zahringer, C., BelAiba, R. S., Djordjevic, T., Hess, J., Michiels, C., Kietzmann, T., and Görlach, A. (2007). Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler. Thromb. Vasc. Biol. 27, 755-761.
18. Brown, A. M., Sease, K. L., Robey, J. L., Shofer, F. S., and Hollander, J. E. (2007). The risk for acute coronary syndrome associated with atrial fibrillation among ED patients with chest pain syndromes. Am. J. Emerg. Med. 25, 523-528.
19. Bruneau, B. G., Piazza, L. A., and de Bold, A. J. (1997). BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am. J. Physiol. 273(Pt 2), H2678-H2686.
20. Brunner, F., Leonhard, B., Kukovetz, W. R., and Mayer, B. (1997). Role of endothelin, nitric oxide and L-arginine release in ischaemia/reperfusion injury of rat heart. Cardiovasc. Res. 36, 60-66.
21. Bukowska, A., Hammwöhner, M., Six-dorf, A., Schild, L., Wiswedel, I. Röhl, F. W., Wolke, C., Lendeckel U., Aderkast, C., Bochmann, S. Chilukoti, R. K., Mostertz, J., Bram-lage, P., and Goette, A. (2012) Dronedarone prevents microcircu-latory abnormalities in the left ventricle during atrial tachypacing. Br J. Pharmacol. 166, 964-980.
22. Bukowska, A., Schild, L., Keilhoff, G. Hirte, D., Neumann, M., Gardemann, A., Neumann, K. H., Röhl F. W., Huth, C., Goette, A., and Lendeckel, U. (2008). Mitochondr-ial dysfunction and redox signaling in atrial tachyarrhythmia. Exp. Biol Med. (Maywood) 233, 558-574.
23. Cadenas, E., Wefers, H., Müller, A. Brigelius, R., and Sies, H. (1982) Active oxygen metabolites and their action in the hepatocyte. Studies on chemiluminescence responses and alkane production. Agents Actions Suppl. 11, 203-216.
24. Camici,P. G., and Crea,F. (2007). Coronary microvascular dysfunction. N Engl. J. Med. 356, 830-840.
25. Cardin, S., Li, D., Thorin-Trescases N., Leung, T. K., Thorin, E., and Nattel, S. (2003). Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res. 60, 315-325.
26. Carnes,C. A., Chung,M. K., Nakayama T., Nakayama, H., Baliga, R. S. Piao, S., Kanderian, A., Pavia, S. Hamlin, R. L., McCarthy, P. M. Bauer, J. A., and Van Wagoner D. R. (2001). Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ. Res 89, E32-E38.
27. Chen,H.,Li,D.,Sawamura,T.,Inoue,K. and Mehta, J. L. (2000). Upregula-tion of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem. Bio-phys. Res. Commun. 276, 1100-1104
28. Chen, K., Kirber, M. T., Xiao, H., Yang Y., and Keaney, J. F. Jr. (2008). Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol. 181, 1129-1139.
29. Connolly, S. J., Camm, A. J., Halperin, J L., Joyner, C., Alings, M., Amerena J., Atar, D., Avezum, Á., Blomström P., Borggrefe, M., Budaj, A., Chen S. A., Ching, C. K., Commerford, P. Dans, A., Davy, J. M., Delacrétaz, E. Di Pasquale, G., Diaz, R., Dorian P., Flaker, G., Golitsyn, S., Gonzalez-Hermosillo, A., Granger, C. B., Heidbüchel, H., Kautzner, J., Kim, J. S. Lanas, F., Lewis, B. S., Merino, J. L., Morillo, C., Murin, J., Narasimhan, C., Paolasso, E., Parkhomenko, A., Peters, N. S., Sim, K. H., Stiles, M. K., Tanomsup,S.,Toivonen,L.,Tom-csányi, J., Torp-Pedersen, C., Tse, H. F., Vardas, P., Vinereanu, D., Xavier, D., Zhu, J., Zhu, J. R., Baret-Cormel, L., Weinling, E., Staiger, C., Yusuf, S., Chrolavicius, S., Afzal, R., Hohn-loser, S. H., and PALLAS Investigators. (2011). Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med. 365, 2268-2276.
30. Dammanahalli, K.J., and Sun, Z. (2008). Endothelins and NADPH oxidases in the cardiovascular system. Clin. Exp. Pharmacol. Physiol. 35, 2-6.
31. De Boer, R. A., Pinto, Y. M., and Van Veldhuisen, D. J. (2003). The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the roleof microvasculargrowthand abnormalities. Microcirculation 10, 113-126.
32. Dikalova, A., Clempus, R., Lassègue, B., Cheng, G., McCoy, J., Dikalov, S., San Martin, A., Lyle, A., Weber, D. S., Weiss, D., Taylor, W. R., Schmidt, H. H., Owens, G. K., Lambeth, J. D., and Griendling, K. K. (2005). NOX1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112, 2668-2676.
33. Doerries, C., Grote, K., Hilfiker-Kleiner, D., Luchtefeld, M., Schaefer, A., Holland, S. M., Sorrentino, S., Manes, C., Schieffer, B., Drexler, H., and Landmesser, U. (2007). Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ. Res. 100, 894-903.
34. Doughan, A. K., Harrison, D. G., and Dikalov, S. I. (2008). Molecular mechanisms of angiotensin II mediated mitochondrial dysfunction. Linking mitochondrial oxida-tive damage and vascular endothe-lial dysfunction. Circ. Res. 102, 488-496.
35. Engelhorn, T., Schwarz, M. A., Heusch, G., Doerfler, A., and Schulz, R. (2011). Reduction of cerebral infarct size by dronedarone. Cardiovasc. Drugs Ther. 25, 523-529.
36. Ferrara, N., Frantz, G., LeCouter, J., Dillard-Telm, L., Pham, T., Draksharapu, A., Giordano, T., and Peale, F. (2003). Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am. J. Pathol. 162, 1881-1893.
37. Fineschi, M., Bravi, A., and Gori, T. (2008). The "slow coronary flow" phenomenon: evidence of preserved coronary flow reserve despite increased resting microvas-cular resistances. Int. J. Cardiol. 127, 358-361.
38. Fontayne, A., Dang, P. M., Gougerot-Pocidalo, M. A., and El-Benna, J. (2002).Phosphorylationof p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry 41, 7743-7750.
39. Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J. Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., Smith, S. C. Jr., Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman,E. M., Halperin,J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., Priori, S. G., Blanc, J. J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., and Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114, e257-e354.
40. Galatius-Jensen, S., Wroblewski, H., Emmeluth, C., Bie, P., Haunsø, S., and Kastrup, J. (1996). Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc. Res. 32, 1148-1154.
41. Ghezzi, P., Bonetto, V., and Fratelli, M. (2005). Thiol-disulfide balance: from the concept of oxidative stress to that of redox regulation. Antioxid. Redox Signal. 7, 964-972.
42. Goette, A., Bukowska, A., Dobrev, D., Pfeiffenberger, J., Morawietz, H., Strugla, D., Wiswedel, I., Röhl, F.-W., Wolke, C., Bergmann, S., Bramlage, P., Ravens, U., and Lendeckel, U. (2009). Acute atrial tachyarrhyth-mia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur. Heart J. 30, 1411-1420.
43. Goette, A., Bukowska, A., Lendeckel, U., Erxleben, M., Hammwohner, M., Strugala, D., Pfeiffenberger, J., Rohl, F. W., Huth, C., Ebert, M. P., Klein, H. U., and Rocken, C. (2008). Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 117, 732-742.
44. Goette, A., Staack, T., Rocken, C.,Arndt, M., Geller, J. C., Huth, C., Ansorge, S., Klein, H. U., and Lendeckel, U. (2000). Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. Cardiol. 35, 1669-1677.
45. Griendling, K. K., Sorescu, D., and Ushio-Fukai, M. (2000). NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86, 494-501.
46. Hasdai, D., Kornowski, R., and Battler, A. (1994). Endothelin and myocar-dial ischemia. Cardiovasc. Drugs Ther. 8, 589-599.
47. Heusch, G. (2008). Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br. J. Pharmacol. 153, 1589-1601.
48. Heusch, G., Baumgart, D., Cam-ici, P., Chilian, W., Gregorini, L., Hess, O., Indolfi, C., and Rimoldi, O. (2000). Alpha-adrenergic coronary vasoconstriction and myocar-dial ischemia in humans. Circulation 101, 689-694.
49. Hiller, K. H., Roder, F., Adami, P., Voll, S., Kowallik, P., Haase, A., Ertl, G., and Bauer, W. R. (1997). Study of microcirculation by coloured microspheres and NMR-microscopy in isolated rat heart: effect of ischaemia, endothelin-1 and endothelin-1 antagonist BQ 610. J. Mol. Cell. Cardiol. 29, 3115-3122.
50. Hingtgen, S. D., Tian, X., Yang, J., Dun-lay, S. M.,Peek,A. S., Wu, Y., Sharma, R. V., Engelhardt, J. F., and Davisson, R. L. (2006). Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol. Genomics 26, 180-191.
51. Hohnloser, S. H., Crijns, H. J., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., Connolly, S. J., and ATHENA Investigators. (2009). Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668-678.
52. Jaimes, E. A., Galceran, J. M., and Raij, L. (1998). Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int. 54, 775-784.
53. Jones, D. P. (2006). Redefining oxida-tive stress. Antioxid. Redox Signal. 8, 1865-1879.
54. Jones, D. P. (2008). Radical-free biology of oxidative stress.Am. J. Physiol. Cell Physiol. 295, C849-C868.
55. Kern, M. J., Lerman, A., Bech, J. W., De Bruyne, B., Eeckhout, E., Fearon, W. F., Higano, S. T., Lim, M. J., Meuwis-sen, M., Piek, J. J., Pijls, N. H., Siebes, M., and Spaan, J. A. (2006). Physiological assessmentof coronary artery disease in the cardiac catheterization laboratory: a scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheteriza-tion, Councilon Clinical Cardiology. Circulation 114, 1321-1341.
56. Kim, J. W., Tchernyshyov, I., Semenza, G. L., and Dang, C. V. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177-185.
57. Kim, Y. M., Kattach, H., Ratnatunga, C., Pillai, R., Channon, K. M., and Casadei, B. (2008). Association of atrial nicotinamide adenine dinu-cleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J. Am. Coll. Cardiol. 51, 68-74.
58. Kinoshita, O., Yoshimi, H., Nagata, S., Ishikura, F., Kimura, K., Yamabe, T., Takagaki, K., Miyatake, K., and Omae, T. (1993). Rapid increase in plasma endothelin concentrations during percutaneous balloon dilatation of the mitral valve in patients with mitral stenosis. Br. Heart J. 69, 322-326.
59. Kiriakidis, S., Andreakos, E., Monaco, C., Foxwell, B., Feldmann, M., and Paleolog, E. (2003). VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor Ikappa-Balpha and a kinase-defective form of the IkappaB kinase 2. J. Cell. Sci. 116, 665-674.
60. Kochiadakis, G. E., Skalidis, E. I., Kalebubas, M. D., Igoumenidis, N. E., Chrysostomakis, S. I., Kanoupakis, E. M., Simantirakis, E. N., and Vardas, P. E. (2002). Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans.Eur. HeartJ.23,734-741.
61. Korantzopoulos, P., Kolettis, T. M., Kountouris, E., Dimitroula, V., Karanikis, P., Pappa, E., Siogas, K., and Goudevenos, J. A. (2005). Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int. J. Cardiol. 102, 321-326.
62. Kunsch, C., and Medford, R. M. (1999). Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. 85, 753-766.
63. Kuroda, J.,Ago, T., Matsushima, S., Zhai, P., Schneider, M. D., and Sadoshima, J. (2010). NADPH oxidase4 (NOX4) is a major source of oxidative stress in the failing heart. Proc. Natl. Acad. Sci. U.S.A. 107, 15565-15570.
64. Lawrence, D. M., Seth, P., Durham, L., Diaz, F., Boursiquot, R., Ransohoff, R. M., and Major, E. O. (2006). Astrocyte differentiation selectively upregulates CCL2/monocyte chemoattractant protein-1 in cultured human brain-derived progenitor cells. Glia 53, 81-91.
65. Li, J. M., Gall, N. P., Grieve, D. J., Chen, M., and Shah, A. M. (2002). Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40, 477-484.
66. Li, J. M., and Shah, A. M. (2003). ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J. Am. Soc. Nephrol. 14(Suppl. 3), S221-S226.
67. 2+ signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate(IP3)-receptor type 2-deficient mice. Circ. Res. 96, 1274-1281.
68. Li, Y. L., Gao, L., Zucker, I. H., and Schultz, H. D. (2007). NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits. Cardio-vasc. Res. 75, 546-554.
69. Lillig, C. H., and Holmgren, A. (2007). Thioredoxin and related molecules - from biology to health and disease. Antioxid. Redox Signal. 9, 25-47.
70. Lin,Y. K., Lai, M. S., Chen,Y. C., Cheng, C. C., Huang, J. H., Chen, S. A., Chen, Y. J., and Lin, C. I. (2012). Hypoxia and reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin. Sci. 122, 121-132.
71. Love, M. P., Ferro, C. J., Haynes, W. G., Plumpton, C., Davenport, A. P., Webb, D. J., and McMurray, J. J. (2000). Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc. Res. 47, 166-172.
72. Martin, D., Galisteo, R., and Gutkind, J. S. (2009). CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 284, 6038-6042.
73. Matsuno, K., Yamada, H., Iwata, K., Jin, D., Katsuyama, M., Matsuki, M., Takai, S., Yamanishi, K., Miyazaki, M., Matsubara, H., and Yabe-Nishimura, C. (2005). NOX1 is involved in angiotensin II-mediated hypertension: a study in NOX1-deficient mice. Circulation 112, 2677-2685.
74. Matsuzawa, A., and Ichijo, H. (2008). Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim. Biophys. Acta 1780, 1325-1336.
75. Mayyas, F., Niebauer, M., Zurick, A., Barnard, J., Gillinov, A. M., Chung, M. K., and Van Wagoner, D. R. (2010). Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ. Arrhythm. Electrophysiol. 3, 369-379.
76. Mollnau, H., Wendt, M., Szöcs, K., Lassègue, B., Schulz, E., Oelze, M., Li, H., Bodenschatz, M., August, M., Kleschyov, A. L., Tsilimingas, N., Walter, U., Förstermann, U., Mein-ertz, T., Griendling, K., and Münzel, T. (2002). Effects of angiotensin II infusionon the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 90, E58-E65.
77. Murdoch, C. E., Zhang, M., Cave, A. C., and Shah, A. M. (2006). NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc. Res. 71, 208-215.
78. Nagase, T., Fukuchi, Y., Jo, C., Teramoto, S., Uejima, Y., Ishida, K., Shimizu, T., and Orimo, H. (1990). Endothelin-1 stimulates arachido-nate 15-lipoxygenase activity and oxygen radical formation in the rat distal lung. Biochem. Biophys. Res. Commun. 168, 485-489.
79. Neubauer, S., Zimmermann, S., Hirsch, A., Pulzer, F., Tian, R., Bauer, W., Bauer, B., and Ertl, G. (1991). Effects of endothelin-1 in the isolated heart in ischemia/reperfusion and hypoxia/reoxygenation injury. J. Mol. Cell. Cardiol. 23, 1397-1409.
80. Nishida, K., Qi, X. Y., Wakili, R., Comtois, P., Chartier, D., Harada, M., Iwasaki, Y. K., Romeo, P., Maguy, A., Dobrev, D., Michael, G., Talajic, M., and Nattel, S. (2011). Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. Circulation 123, 137-146.
81. Oudot, A., Vergely, C., Ecarnot-Laubriet, A., and Rochette, L. (2003). Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia-reperfusion. Eur. J. Pharmacol. 462, 145-154.
82. Qiu, X. B., Shao, Y. M., Miao, S., and Wang, L. (2006). The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell. Mol. Life Sci. 63, 2560-2570.
83. Range, F. T., Schafers, M., Acil, T., Schafers,K. P., Kies, P., Paul, M., Hermann, S., Brisse, B., Breithardt, G., Schober, O., and Wichter, T. (2007). Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. Eur. Heart J. 28, 2223-2230.
84. Reilly, S. N., Jayaram, R., Nahar, K., Antoniades, C., Verheule, S., Chan-non, K. M., Alp, N. J., Schotten, U., and Casadei, B. (2011). Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 124, 1107-1117.
85. Rinckel, L. A., Faris, S. L., Hitt, N. D., and Kleinberg, M. E. (1999). Rac1 disrupts p67phox/p40phox binding: a novel role for Rac in NADPH oxi-dase activation. Biochem. Biophys. Res. Commun. 263, 118-122.
86. Rivard, L., Sinno, H., Shiroshita-Takeshita, A., Schram, G., Leung, T. K., and Nattel, S. (2007). The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy. Cardiovasc. Res. 74, 104-113.
87. Rubens, C., Ewert, R., Halank, M., Wensel, R., Orzechowski, H. D., Schultheiss, H. P., and Hoeffken, G. (2001). Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonaryhypertension.Chest 120, 1562-1569.
88. Satoh, M., Ogita, H., Takeshita, K., Mukai, Y., Kwiatkowski, D. J., and Liao, J. K. (2006). Requirement of Rac1 in the development of cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 103, 7432-7437.
89. Seagroves, T. N., Ryan, H. E., Lu, H., Wouters,B. G., Knapp, M., Thibault, P., Laderoute, K., and Johnson, R. S. (2001). Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol. Cell. Biol. 21, 3436-3444.
90. Serrander, L., Cartier, L., Bedard, K., Banfi, B., Lardy, B., Plastre, O., Sienkiewicz, A., Fórró, L., Schlegel, W., and Krause, K. H. (2007). NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem. J. 406, 105-114.
91. Shohet, R. V., and Garcia, J. A. (2007). Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia. J. Mol. Med. 85, 1309-1315.
92. Sinno, H., Derakhchan, K., Liber-san, D., Merhi, Y., Leung, T. K., and Nattel, S. (2003). Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107, 1930-1936.
93. Skyschally, A., and Heusch, G. (2011). Reduction of myocardial infarct size by dronedarone in pigs - a pleiotropic action? Cardiovasc. Drugs Ther. 25, 197-201.
94. Sugden, P. H. (2003). An overview of endothelin signaling in the cardiac myocyte. J. Mol. Cell. Cardiol. 35, 871-886.
95. Takahashi, N., Ishibashi, Y., Shimada, T., Sakane, T., Ohata, S., Sug-amori, T., Ohta, Y., Inoue, S., Nakamura, K., Shimizu, H., Katoh, H., and Murakami, Y. (2002). Impaired exercise-induced vasodi-latation in chronic atrial fibrillation - role of endothelium-derived nitric oxide. Circ. J. 66, 583-538.
96. Van Gelder, I. C., Hagens, V. E., Bosker, H. A., Kingma, J. H., Kamp, O., Kingma, T., Said, S. A., Darmanata, J. I., Timmermans, A. J., Tijssen, J. G., and Crijns, H. J. (2002). A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834-1840.
97. White, M., Rouleau, J. L., Hall, C., Arnold, M., Harel, F., Sirois, P., Greaves, S., Solomon, S., Ajani, U., Glynn, R., Hennekens, C., and Pfeffer, M. (2001). Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. Am. Heart J. 142, 1056-1064.
98. Wyse, D. G., Waldo, A. L., DiMarco, J. P., Domanski, M. J., Rosenberg, Y., Schron, E. B., Kellen, J. C., Greene, H. L., Mickel, M. C., Dalquist, J. E., and Corley, S. D. (2002). A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833.
99. Yasunari, K., Maeda, K., Nakamura, M., and Yoshikawa, J. (2002). Pressure promotes angiotensin II - mediated migration of human coronary smooth muscle cells through increase in oxidative stress. Hypertension 39(2 Pt 2), 433-437.
100. Zhang, Y., Griendling, K. K., Dikalova, A., Owens, G. K., and Taylor, W. R. (2005). Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2. Hypertension 46, 732-737.
101. Zolk, O., Quattek, J., Sitzler, G., Schrader, T., Nickenig, G., Schn-abel, P., Shimada, K., Takahashi, M., and Böhm, M. (1999). Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 99, 2118-2123.